113 related articles for article (PubMed ID: 26231160)
1. Novel oxazolidinone calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraine.
Crowley BM; Stump CA; Nguyen DN; Potteiger CM; McWherter MA; Paone DV; Quigley AG; Bruno JG; Cui D; Culberson JC; Danziger A; Fandozzi C; Gauvreau D; Kemmerer AL; Menzel K; Moore EL; Mosser SD; Reddy V; White RB; Salvatore CA; Kane SA; Bell IM; Selnick HG; Fraley ME; Burgey CS
Bioorg Med Chem Lett; 2015 Nov; 25(21):4777-4781. PubMed ID: 26231160
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine.
Salvatore CA; Hershey JC; Corcoran HA; Fay JF; Johnston VK; Moore EL; Mosser SD; Burgey CS; Paone DV; Shaw AW; Graham SL; Vacca JP; Williams TM; Koblan KS; Kane SA
J Pharmacol Exp Ther; 2008 Feb; 324(2):416-21. PubMed ID: 18039958
[TBL] [Abstract][Full Text] [Related]
3. Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine.
Rudolf K; Eberlein W; Engel W; Pieper H; Entzeroth M; Hallermayer G; Doods H
J Med Chem; 2005 Sep; 48(19):5921-31. PubMed ID: 16161996
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor.
Shi L; Lehto SG; Zhu DX; Sun H; Zhang J; Smith BP; Immke DC; Wild KD; Xu C
J Pharmacol Exp Ther; 2016 Jan; 356(1):223-31. PubMed ID: 26559125
[TBL] [Abstract][Full Text] [Related]
5. Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: discovery of MK-2918.
Paone DV; Nguyen DN; Shaw AW; Burgey CS; Potteiger CM; Deng JZ; Mosser SD; Salvatore CA; Yu S; Roller S; Kane SA; Selnick HG; Vacca JP; Williams TM
Bioorg Med Chem Lett; 2011 May; 21(9):2683-6. PubMed ID: 21251825
[TBL] [Abstract][Full Text] [Related]
6. Caprolactams as potent CGRP receptor antagonists for the treatment of migraine.
Shaw AW; Paone DV; Nguyen DN; Stump CA; Burgey CS; Mosser SD; Salvatore CA; Rutledge RZ; Kane SA; Koblan KS; Graham SL; Vacca JP; Williams TM
Bioorg Med Chem Lett; 2007 Sep; 17(17):4795-8. PubMed ID: 17616394
[TBL] [Abstract][Full Text] [Related]
7. CGRP-receptor antagonism in migraine treatment.
Edvinsson L
Lancet; 2008 Dec; 372(9656):2089-90. PubMed ID: 19036426
[No Abstract] [Full Text] [Related]
8. Potent oxadiazole CGRP receptor antagonists for the potential treatment of migraine.
Nichols PL; Brand J; Briggs M; D'Angeli M; Farge J; Garland SL; Goldsmith P; Hutchings R; Kilford I; Li HY; MacPherson D; Nimmo F; Sanderson FD; Sehmi S; Shuker N; Skidmore J; Stott M; Sweeting J; Tajuddin H; Takle AK; Trani G; Wall ID; Ward R; Wilson DM; Witty D
Bioorg Med Chem Lett; 2010 Feb; 20(4):1368-72. PubMed ID: 20097071
[TBL] [Abstract][Full Text] [Related]
9. Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: optimization of the 4-substituted piperidine.
Burgey CS; Stump CA; Nguyen DN; Deng JZ; Quigley AG; Norton BR; Bell IM; Mosser SD; Salvatore CA; Rutledge RZ; Kane SA; Koblan KS; Vacca JP; Graham SL; Williams TM
Bioorg Med Chem Lett; 2006 Oct; 16(19):5052-6. PubMed ID: 16889959
[TBL] [Abstract][Full Text] [Related]
10. Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
Bell IM
J Med Chem; 2014 Oct; 57(19):7838-58. PubMed ID: 24960305
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.
Ho TW; Ferrari MD; Dodick DW; Galet V; Kost J; Fan X; Leibensperger H; Froman S; Assaid C; Lines C; Koppen H; Winner PK
Lancet; 2008 Dec; 372(9656):2115-23. PubMed ID: 19036425
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries.
Lynch JJ; Regan CP; Edvinsson L; Hargreaves RJ; Kane SA
J Cardiovasc Pharmacol; 2010 May; 55(5):518-21. PubMed ID: 20164785
[TBL] [Abstract][Full Text] [Related]
13. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development.
Bigal ME; Walter S; Rapoport AM
Headache; 2013 Sep; 53(8):1230-44. PubMed ID: 23848260
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of novel alpha-Calcitonin Gene-Related Peptide (CGRP) receptor peptide antagonists that are selective for human CGRP receptors.
Taylor CK; Smith DD; Hulce M; Abel PW
J Pharmacol Exp Ther; 2006 Nov; 319(2):749-57. PubMed ID: 16873605
[TBL] [Abstract][Full Text] [Related]
15. In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232.
Hostetler ED; Joshi AD; Sanabria-Bohórquez S; Fan H; Zeng Z; Purcell M; Gantert L; Riffel K; Williams M; O'Malley S; Miller P; Selnick HG; Gallicchio SN; Bell IM; Salvatore CA; Kane SA; Li CC; Hargreaves RJ; de Groot T; Bormans G; Van Hecken A; Derdelinckx I; de Hoon J; Reynders T; Declercq R; De Lepeleire I; Kennedy WP; Blanchard R; Marcantonio EE; Sur C; Cook JJ; Van Laere K; Evelhoch JL
J Pharmacol Exp Ther; 2013 Nov; 347(2):478-86. PubMed ID: 23975906
[TBL] [Abstract][Full Text] [Related]
16. Calcitonin gene-related peptide (CGRP) receptor antagonists: pyridine as a replacement for a core amide group.
Luo G; Chen L; Civiello R; Pin SS; Xu C; Kostich W; Kelley M; Conway CM; Macor JE; Dubowchik GM
Bioorg Med Chem Lett; 2012 Apr; 22(8):2917-21. PubMed ID: 22429470
[TBL] [Abstract][Full Text] [Related]
17. Examining the binding properties of MK-0974: a CGRP receptor antagonist for the acute treatment of migraine.
Moore EL; Burgey CS; Paone DV; Shaw AW; Tang YS; Kane SA; Salvatore CA
Eur J Pharmacol; 2009 Jan; 602(2-3):250-4. PubMed ID: 19084002
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist.
Salvatore CA; Moore EL; Calamari A; Cook JJ; Michener MS; O'Malley S; Miller PJ; Sur C; Williams DL; Zeng Z; Danziger A; Lynch JJ; Regan CP; Fay JF; Tang YS; Li CC; Pudvah NT; White RB; Bell IM; Gallicchio SN; Graham SL; Selnick HG; Vacca JP; Kane SA
J Pharmacol Exp Ther; 2010 Apr; 333(1):152-60. PubMed ID: 20065019
[TBL] [Abstract][Full Text] [Related]
19. MK-8825: a potent and selective CGRP receptor antagonist with good oral activity in rats.
Bell IM; Stump CA; Gallicchio SN; Staas DD; Zartman CB; Moore EL; Sain N; Urban M; Bruno JG; Calamari A; Kemmerer AL; Mosser SD; Fandozzi C; White RB; Zrada MM; Selnick HG; Graham SL; Vacca JP; Kane SA; Salvatore CA
Bioorg Med Chem Lett; 2012 Jun; 22(12):3941-5. PubMed ID: 22607672
[TBL] [Abstract][Full Text] [Related]
20. A novel formulation of veggies with potent anti-migraine activity.
Jain MM; Kumari N; Rai G
Int J Comput Biol Drug Des; 2015; 8(1):54-61. PubMed ID: 25869319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
